1-9 of 9
Peter Ganly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Clinical Trials & Observations
Hervé Avet-Loiseau, Nizar J. Bahlis, Wee-Joo Chng, Tamas Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Antonio Palumbo, Michele Cavo, Christian Langer, Andrzej Pluta, Arnon Nagler, Shaji Kumar, Dina Ben-Yehuda, S. Vincent Rajkumar, Jesus San-Miguel, Deborah Berg, Jianchang Lin, Helgi van de Velde, Dixie-Lee Esseltine, Alessandra di Bacco, Philippe Moreau, Paul G. Richardson
Journal: Blood
Blood (2017) 130 (24): 2610–2618.
https://doi.org/10.1182/blood-2017-06-791228
Published: 2017
Includes: Supplemental data
Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison
Journal: Blood
Blood (2016) 128 (22): 3131.
https://doi.org/10.1182/blood.V128.22.3131.3131
Published: 2016
Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Alessandra Di Bacco, PhD, Nizar J. Bahlis, MD, Nikhil C Munshi, MD, Hervé Avet-Loiseau, MD PhD, Tamás Masszi, MD, Luísa Viterbo, MD, Ludek Pour, MD PhD, Peter Ganly, BMBCh, PhD, Michele Cavo, MD, Christian Langer, MD, Shaji Kumar, MD, S. Vincent Rajkumar, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, PhD, Dixie-Lee Esseltine, MD, Katarina Luptakova, Helgi van de Velde, MD PhD, Paul G. Richardson, MD, Philippe Moreau
Journal: Blood
Blood (2016) 128 (22): 243.
https://doi.org/10.1182/blood.V128.22.243.243
Published: 2016
Journal Articles

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

Moritz Gerstung, PhD, Elli Papaemmanuil, PhD, Inigo Martincorena, PhD, Lars Bullinger, MD, Verena I. Gaidzik, MD, Peter Paschka, MD, Michael Heuser, MD, Felicitas Thol, MD, Niccolo Bolli, MD PhD, Peter Ganly, BMBCh, PhD, Arnold Ganser, MD, Ultan McDermott, MD PhD, Michael R Stratton, MD PhD, Konstanze Döhner, MD, Hartmut Döhner, Prof. Dr., Richard F. Schlenk, MD, Peter J Campbell, MD PhD
Journal: Blood
Blood (2015) 126 (23): 85.
https://doi.org/10.1182/blood.V126.23.85.85
Published: 2015
Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, MD, Norbert Grzasko, MD PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 727.
https://doi.org/10.1182/blood.V126.23.727.727
Published: 2015
Journal Articles

A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma

Niccolo Bolli, MD PhD, Graham R Bignell, PhD, Peter Ganly, BMBCh, PhD, Elli Papaemmanuil, PhD, Herve Avet-Loiseau, Adam Sperling, MD PhD, Stephane Minvielle, Peter J Campbell, PhD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2014) 124 (21): 3364.
https://doi.org/10.1182/blood.V124.21.3364.3364
Published: 2014
Journal Articles

Successful Treatment of Transplant Associated Microangiopathy with Rituximab

Peter Ganly, Helen Marr, Emma-Jane McDonald, Eileen Merriman, Hilda Mangos, Catherine Stoddart, Mark Smith
Journal: Blood
Blood (2008) 112 (11): 4337.
https://doi.org/10.1182/blood.V112.11.4337.4337
Published: 2008
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008
Journal Articles

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

Kerry Taylor, MD, Peter Ganly, MD, Veena Charu, MD, Joseph DiBenedetto, MD, Karolyn Kracht, PhD, Greg Rossi, PhD, Enrique Hernandez, MD
Journal: Blood
Blood (2005) 106 (11): 3556.
https://doi.org/10.1182/blood.V106.11.3556.3556
Published: 2005